10 Best Penny Stocks That Could Skyrocket in 2026
In this article, we look at the 10 Best Penny Stocks That Could Skyrocket in 2026. Penny stocks can deliver dramatic gains when a business achieves a milestone that investors had discounted.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 9,151,524 | $10,432,737 | +411% | 0% |
| 2. | Millennium Management Israel Englander | 3,196,605 | $3,644,130 | +35% | 0% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,000,000 | $2,280,000 | 0.07% | |
| 4. | Citadel Investment Group Ken Griffin | 1,717,659 | $1,958,131 | +24% | 0% |
| 5. | Renaissance Technologies Jim Simons | 1,223,963 | $1,395,318 | -34% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.25 | 69,270 | $86,587.50 | 3,367,064 | 2026-03-04 | Filing | |
| $3.43 | 5,800 | $19,894.00 | 29,731 | 2019-11-20 | Filing | |
| $3.52 | 15,000 | $52,800.00 | 28,700 | 2019-11-20 | Filing | |
| $3.58 | 27,000 | $96,660.00 | 37,000 | 2019-11-20 | Filing | |
| $3.44 | 50,000 | $172,000.00 | 887,732 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.11 | 56,019 | $62,181.09 | 616,616 | 2026-06-29 | Filing | |
| $1.39 | 13,382 | $18,600.98 | 299,390 | 2026-02-02 | Filing | |
| $1.39 | 36,142 | $50,237.38 | 312,772 | 2026-02-02 | Filing | |
| $1.39 | 31,244 | $43,429.16 | 561,750 | 2026-02-02 | Filing | |
| $1.39 | 53,585 | $74,483.15 | 592,994 | 2026-02-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 868,227 | $798,769 | 0.02% | |
| 2. | 192,008 | $176,647 | 0.01% | |
| 3. | 106,300 | $97,796 | 0% | |
| 4. | 101,310 | $93,205 | 0% | |
| 5. | 43,000 | $39,560 | 0% |
News See All
11 Best 52-Week Low Penny Stocks to Invest In
In this article, we look at the 11 Best 52-Week Low Penny Stocks to Invest In.
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list.
12 Best Low-Priced Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript May 7, 2026Akebia Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.01.
10 Best Penny Stocks That Could Triple Your Money
In this article, we will take a look at the 10 best penny stocks that are currently offering more than 200% upside potential to investors.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript February 26, 2026Akebia Therapeutics, Inc. misses on earnings expectations.
Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years.
10 Best Growth Stocks to Buy for the Next 20 Years
On February 13, Chief Market Strategist at Carson Group Ryan Detrick and CEO of MCC Global Enterprises Michelle Caruso-Cabrera joined CNBC to discuss rising geopolitical tensions, tariff shifts, and whether...
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics announced the official establishment of its rare kidney disease pipeline.
Hedge Fund Resource Center